For Public Review and Comments. Stakeholder's may provide comments within 45 days of upload of the amendments to This email address is being protected from spambots. You need JavaScript enabled to view it.

 

          Monographs

 

1. Aceclofenac and paracetamol Tablets (10.10.2022)

2.  Amlodipine and Olmesartan Medoxomil Tablets (18.10.2022)

3.  Atropine Ophthalmic solution (10.10.2022)

4.  Azacitidine for Injection  (10.10.2022)

5.  Azilsartan Kamedoxomil (18.10.2022)

6.  Bisoprolol Tablets (18.10.2022)

7.  Brivaracetam Injection (18.10.2022)

8.  Brivaracetam Oral Solution (18.10.2022)

9.  Cabozantinib Tablets (18.10.2022)

10. Cabozantinib-S-Malate (18.10.2022)

11.  Calcium Polystyrene Sulphonate (18.10.2022)

12.  Cetirizine Hydrochloride Oral Solution (18.10.2022)

13.  Dasatinib (18.10.2022)

14.  Dasatinib Tablets (18.10.2022)

15.  Ethamsylate (10.10.2022)

16.  Ibuprofen Oral Suspension (18.10.2022)

17.  Ketoconazole Shampoo (18.10.2022)

18.  Lactulose Solution (10.10.2022)

19.  Mefenamic acid suspension (18.10.2022)

20.  Moxifloxacin Tablets (10.10.2022)

21.  Paracetamol and Tramadol Tablets (18.10.2022)

22.  Perampanel (18.10.2022)

23.  Perampanel Tablets (18.10.2022)

24.  Remogliflozin Tablets (10.10.2022)

25.  Remogliflozin Etabonate (18.10.2022)

26.  Sodium Polystyrene Sulphonate (18.10.2022)

27.  Sodium Stearyl Fumarate (18.10.2022)

28.  Xylitol (18.10.2022)

29.  Copovidone (28.11.2022)

30.  Lindane Lotion (28.11.2022)

31.  Molnupiravir (28.11.2022)

32.  Molnupiravir Capsules (28.11.2022)

33.  Gliclazide Prolonged Release Tablets (28.11.2022)

34.  Rifaximin (28.11.2022)

35.  Rifaximin Tablets (28.11.2022)

36.  Velpatasvir (28.11.2022)

37.  Sofosbuvir and Velpatasvir Tablets (28.11.2022)

 

News & Highlights


View All

IPC Products

ip nfi
 
Connect with IPC